Modular Medical shares surge 39.31% after-hours after validating Pivot controller line for Q1 2026 launch.

Modular Medical surged 39.31% in after-hours trading following the announcement of successful validation of its Pivot controller line, a critical step toward its Q1 2026 commercial launch. The news confirmed manufacturing readiness for high-volume production of the tubeless, removable 3-milliliter patch pump, targeting a $3 billion market for adult "almost-pumpers." The milestone, emphasized in multiple press releases, reduces commercialization risks and positions the company to scale production efficiently, a key differentiator in the insulin pump sector. CEO Jeb Besser highlighted the achievement as evidence of the company’s ability to meet demand for its user-friendly, affordable device. While regulatory clearance and market acceptance remain pending, the validation directly addresses scalability concerns, aligning with the stock’s sharp post-announcement rally.